Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase I/II, Open-label, Non-controlled, Escalating Dose, Multicentre Clinical Trial Evaluating the Safety, Preliminary Efficacy, and Pharmacokinetics of MP0112 Injected Intravitreally in Patients With Wet Age Related Macular Degeneration (AMD)

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source
ClinicalTrials.gov
Source record ID
NCT01086761
Title field or adapter rule
protocolSection.identificationModule.officialTitle
Ingested At
2026-04-28T10:35:42.681403+00:00
Published At
2014-05-12T00:00:00+00:00
Record Updated At
2014-05-12
Results Posted At
2014-05-12
Timestamp Basis
source retrieval time was not retained by the feed adapter
Date limitation
source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions
["Wet Age-Related Macular Degeneration"]
protocolSection.statusModule.lastUpdatePostDateStruct.date
"2014-05-12"
protocolSection.identificationModule.nctId
"NCT01086761"
protocolSection.identificationModule.officialTitle
"A Phase I/II, Open-label, Non-controlled, Escalating Dose, Multicentre Clinical Trial Evaluating the Safety, Preliminary Efficacy, and Pharmacokinetics of MP0112 Injected Intravitreally in Patients With Wet Age Related Macular Degeneration (AMD)"
protocolSection.statusModule.overallStatus
"TERMINATED"
protocolSection.designModule.phases
["PHASE1"]
protocolSection.statusModule.resultsFirstPostDateStruct.date
"2014-05-12"

Study condition terms

  • Wet Age-Related Macular Degeneration (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.